| abstract |
The present invention provides metabolic markers and applications for rapid diagnosis of multiple myeloma, wherein the metabolic markers include one or more of phenylalanine, tyrosine and tryptophan. Compared with the prior art, the present invention has the following advantages: the present invention provides metabolic markers and applications for rapid diagnosis of multiple myeloma, and the markers are derived from one or more metabolites in the patient's bone marrow tissue and bone marrow supernatant. A variety of combinations, including phenylalanine, tyrosine and tryptophan; the detection of metabolic marker levels can be effectively used for early clinical diagnosis of multiple myeloma disease, with high sensitivity, fast and convenient, accurate and reliable results, and can be used for It provides a basis for clinical decision-making and a certain basis for subsequent basic and clinical research, which has potential application and research value. |